ABSTRACT The dose-response relationships of ipratropium bromide were assessed by two different techniques in two groups of 10 male patients with partially reversible airways obstruction. In a randomised double-blind fashion on four days, 10 patients were given 40 jug, 80 ,ug, or 120 ,ug of ipratropium bromide or placebo from identical containers. Baseline FEV, and vital capacity were measured and the measurements repeated after 40 minutes, one, two, four, and six hours, and any symptoms were elicited. In the second study, each patient received cumulative doses of 40 ,ug, 80 ug, and 120 ,ug. Baseline FEV, was obtained and repeated 35 minutes after each dose. The peak increase of the FEV, was comparable in both studies. The FEV, was slightly greater after 120 ,ug than after 40 ug. Although this reached statistical significance only in the first study, it was concluded that the cumulative dose-response technique was suitable for determining the peak response. However, this technique was unsuitable for assessing duration of effect, which could be examined only in the first study. After 120 ,ug of ipratropium bromide, the FEV1 was significantly greater than after 40 jug at each time interval and it was greater than 80 ug at six hours (p<005). No significant side effects were noted in either study. When prolonged effective bronchodilation is sought, a dose of 120 ,g of ipratropium bromide may be preferable to the recommended dose of 40 ,ug.
The anticholinergic bronchodilator ipratropium bromide is a quarternary ammonium derivative of atropine. Its quarternary structure prevents it crossing the blood-brain barrier and causing central effects. As an aerosol it is highly specific and virtually free of side effects even in doses well in excess of those recommended.1 2 It has been reported that the recommended dose, 40 ,tg from a metered dose inhaler, achieves a peak bronchodilator effect.3 Nevertheless, higher doses may prolong the duration of bronchodilatation4 5.
To assess both the peak bronchodilation and the duration of the response, we have determined the dose-response relationships of ipratropium bromide with two different techniques. In the first study we administered the test doses on different days. In this way we were able to assess the peak response, duration of action, and unwanted side effects. The second study employed a cumulative dose-response technique.6 It is simpler and allows several doses of a drug to be assessed over a short Address for reprint requests. Dr AH Campbell, Repatriation General Hospital, Heidelberg 3077, Australia.
period of time, and the peak effect and unwanted effects can be determined. Its limitation is that it does not allow the duration of action to be assessed.
Methods
A group of 16 male patients gave informed consent to taking part in the investigation. All had asthma characterised by episodes of wheeze and shortness of breath requiring bronchodilators for relief of symptoms, and 12 were receiving beclamethasone dipropionate by inhalation or oral corticosteroids or both. Only six of the 16 patients had positive skin tests to common allergens and all but one had chronic productive cough. Eleven were current cigarette smokers.
SINGLE DOSE STUDIES
For the first study, 10 male patients were admitted to hospital in a stable condition. Bronchodilators were withheld for at least nine hours before any test. However, steroids were continued unchanged.
In a randomised, double-blind fashion on four 137 days (consecutive where possible), the 10 patients studied were given 40 ,ug, 80 ,ig, or 120 ,ug of aerosol ipratropium bromide or placebo from identical containers. Two unlabelled containers were used, containing either placebo or active agent (20 ,ug per puff), so that the patient each day received six puffs of aerosol over 90 seconds.
Each study started at about 0900 hr. Baseline measurements of forced expiratory volume in one second (FEV1) and vital capacity (VC) were performed, and the best of three readings taken. The patient then inhaled the aerosol. At 40 minutes, one, two, four, and six hours after the aerosol measurements of FEV1 and VC were performed. Again the best of three measurements was taken, corrected to BTPS. Symptoms were recorded before each measurement. Baseline measurements each day were within 15% of each other. Tests were postponed when the baseline values were outside this range. The significance of the results obtained was analysed using analysis of variance.
CUMULATIVE DOSE-RESPONSE STUDY
For the cumulative dose-response study, 10 male outpatients were assessed (four common to the first study). Bronchodilators were withheld as before.
The peak effect of ipratropium bromide is not reached until about 30-40 minutes.3 This peak is then maintained for two to three hours. For fig 1) . Apart from a dry cough in one patient after 120 ,ug there were no side effects. 
